FDA warns against HIV drug in premature babies; KV Pharma to launch prenatal med next week;

@FiercePharma: Sanofi's European revamp may kill 700 jobs. Story | Follow @FiercePharma

> U.S. health officials cautioned against the use of Abbott Laboratories' HIV drug Kaletra in premature babies because they could be at greater risk for serious and possibly fatal side effects. Report

> Shares of KV Pharmaceutical surged 31 percent after the drugmaker announced its launch date next week for a prenatal drug. News

> Walgreen plans to sell its pharmacy benefit management business to Catalyst Health Solutions in a $525 million cash deal that would allow Walgreen to focus on its drugstore and healthcare businesses. Story

> The establishment of a European and Community Patent Court, as proposed by the Council of the European Union (EU), is incompatible with EU law, the EU Court of Justice has said. Item

> GlaxoSmithKline has withdrawn Lucozade Sport Lite Summer Berries from retailers and distributors due to "mold growth." Report

> Diagnostic test maker Sequenom said its fourth-quarter loss widened on a charge and higher costs and expenses. Article

> Johnson & Johnson's Janssen unit won EU approval to market its injectable antipsychotic Xeplion for the treatment of schizophrenia. News

> Florida distributed more than a half-billion doses of the pain drug oxycodone in 2009, twice as many as the next nearest state and up sharply from the previous year, newly obtained federal figures show. Item

Biotech News

@FierceBiotech: Sanofi puts European units on chopping block. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see some groups attack pharma for overstating R&D costs while investors demand to know why ROI is so bad for the industry. Follow @JohnCFierce

> Lilly's Lechleiter predicts Amyvid OK, promises R&D successes. Story

> FDA experts turn thumbs down on Novartis's high-dose COPD drug. Report 

> Fledgling cancer vax biotech raises $15M in Series A. Item

> Analysts jolted by Pharmasset's stellar data on combo hep C treatment. News 

Drug Delivery News

> FDA takes aim at some XR cold meds. News

> Alkermes's microsphere tech key to Bydureon. Story 

> SkyePharma stumbles after AstraZeneca decision on asthma drug. Item

> UPenn drug-delivery vector aims to avoid immune attacks. Article

> A crop of anti-pain meds rigged to thwart abuse. Report

Medical Device News

> J&J unit recalls potentially leaky insulin pump cartridges. Story 

> J&J's Cordis unit hit with warning letter on stents. Article 

> Medtronic opens regional HQ building in Shanghai. Report 

> Halma to buy Medicel for $75.5M. Item 

> Fenwal, Golden Meditech to form JV in China. News 

> NovaShunt raises $25M in Series B financing round. Story 

> Fresenius acquires assets from Hema Metrics. Item

And Finally... The U.S. Justice Department said in a court filing that it will appeal a federal judge's Jan. 31 ruling striking down President Barack Obama's healthcare reform legislation. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.